80%
Hopkins 2019: Users reporting depression/anxiety improvement (n=362)
15-30
Minutes — typical duration of a 5-MeO-DMT experience
5x
More potent than N,N-DMT by weight — one of the most potent psychedelics known
CO
First US state with a regulatory framework including 5-MeO-DMT (Prop 122)
14%
Oracle: 5-MeO-DMT FDA approval for depression by 2030
Safety note: 5-MeO-DMT — particularly from Bufo toad venom — carries more acute risk than psilocybin and requires specific precautions. The combination with MAOIs is potentially life-threatening. Bufo venom (unlike synthetic 5-MeO-DMT) contains cardiotoxic co-compounds. This page covers these risks fully. Do not combine 5-MeO-DMT with Syrian rue, harmalas, or other MAO inhibitors under any circumstances.
What Is 5-MeO-DMT? Understanding the Compound
5-methoxy-N,N-dimethyltryptamine is a tryptamine psychedelic occurring naturally in several plant species, the venom of the Sonoran Desert toad (Incilius alvarius), and producible synthetically. It is structurally similar to N,N-DMT but its effects profile is dramatically different — primarily due to its strong 5-HT1A agonism (in addition to 5-HT2A activity).
5-MeO-DMT (This Compound)
Primary mechanism 5-HT1A + 5-HT2A agonism
Duration 15-30 minutes (inhaled)
Experience type Ego dissolution, oceanic boundlessness, unity consciousness — minimal visual component
Sources Sonoran Desert toad (Bufo alvarius), various plants, synthetic
Therapeutic window Very short — integration must happen post-session
Mystical experience Very high frequency of "complete" mystical experience
N,N-DMT (in Ayahuasca)
Primary mechanism 5-HT2A agonism (primary)
Duration 4-6 hours (oral in ayahuasca)
Experience type Rich visual content, entities, narrative experiences — more "processable"
Sources Many plants (DMT-containing), ayahuasca brew
Therapeutic window Long — integration can occur within the session
Mystical experience Common but variable; depends on dose and set
Clinical Research: What Johns Hopkins Found
Johns Hopkins has led the most significant clinical research on 5-MeO-DMT, building on decades of psilocybin expertise. Two landmark publications have shaped the field.
Study 1: Naturalistic Survey (Davis et al., 2019 — Journal of Psychopharmacology)
The largest quantitative study of 5-MeO-DMT outcomes to date. 362 respondents reported on their naturalistic use of 5-MeO-DMT (primarily from Bufo ceremonies in ceremonial retreat settings).
| Outcome Measure | Result |
|---|---|
| Reported improvement in depression | 80% of respondents |
| Reported improvement in anxiety | 79% of respondents |
| Rated experience as among most meaningful in life | 68% |
| Increased life satisfaction reported | 79% |
| Complete mystical experience (MEQ scale) | Significantly higher than typical high-dose psilocybin cohorts |
| Challenging experiences | 32% reported significant psychological difficulty during session |
Caveats: Naturalistic survey — self-selected sample with survivorship bias. People who had severely negative experiences may be underrepresented. Causal inference from survey data is limited.
Study 2: Phase 2 Pilot — Synthetic 5-MeO-DMT for MDD (Hopkins, 2023)
The first controlled clinical administration of synthetic 5-MeO-DMT for major depressive disorder. 10 participants, open-label. A single inhaled session of synthetic 5-MeO-DMT (approximately 18mg) with full psychiatric support.
| Measure | 1-Week Result | 1-Month Result |
|---|---|---|
| MADRS (depression severity) | Significant reduction (effect size ~1.4) | Maintained |
| Remission rate (MADRS ≤10) | 40% | 40% |
| Response rate (50% MADRS reduction) | 60% | 60% |
| Anxiety (GAD-7) | Significant reduction | Maintained |
| Adverse events | Transient: nausea (2), brief confusion (3), one brief hypertensive episode | None serious |
Comparison: 5-MeO-DMT vs. Psilocybin for Depression
| Feature | 5-MeO-DMT | Psilocybin |
|---|---|---|
| Session duration | 15-30 min | 4-8 hours |
| Staff time required | ~2 hours total | 8-10 hours total |
| Response rate (early clinical) | ~60% | ~60-70% |
| Mystical experience rate | Very high (almost universal) | Dose-dependent |
| Visual content | Minimal | Rich, dose-dependent |
| In-session processing | Limited (too brief) | Extended (therapeutic window) |
| Integration challenge | Higher — very intense, short duration | More gradual |
| Scalability (facilitator cost) | Potentially higher (shorter session) | Lower (long session = high cost) |
| Research evidence base | Early-stage (Phase 2) | Phase 3 ongoing |
Bufo Toad Venom vs. Synthetic 5-MeO-DMT: A Critical Distinction
Not all 5-MeO-DMT is the same. The distinction between Bufo toad venom and synthetic 5-MeO-DMT has significant safety, legal, and conservation implications.
⚠️ Bufo Toad Venom
Contains 5-MeO-DMT + bufotenin + bufadienolides (cardiotoxic steroids)
Cardiac risk Bufadienolides can cause arrhythmias — especially dangerous with cardiac conditions, beta blockers, digoxin
Conservation Sonoran Desert toad (Incilius alvarius) under pressure from demand for venom; protected in Arizona (CITES II)
Dosing Variable — difficult to standardize venom potency across individual toads
Research use Not used in any current clinical trials
Legal status Toad is protected; venom possession likely constitutes Schedule I possession
✅ Synthetic 5-MeO-DMT
Contains Pure 5-MeO-DMT only
Cardiac risk No bufadienolides; primarily serotonergic effects only. Lower cardiovascular risk profile.
Conservation No toad harm; eliminates animal welfare concern
Dosing Precisely measured; reproducible across sessions and institutions
Research use Used in all current clinical trials (Hopkins, UCSD)
Legal status Schedule I US federal — same regulatory status as toad venom, but no conservation/animal welfare concern
Critical drug interaction: NEVER combine 5-MeO-DMT (from any source) with MAO inhibitors — including Syrian rue (Peganum harmala), harmalas, or pharmaceutical MAOIs. This combination can cause fatal serotonin syndrome. This interaction is distinct from psilocybin's relatively benign SSRI interaction and represents a genuine life-threatening risk. Any ceremonial setting offering 5-MeO-DMT following an ayahuasca ceremony (which contains MAOIs) is medically dangerous.
Global Legal Status of 5-MeO-DMT
🇺🇸 United States
Schedule I FederalSchedule I under the CSA. Colorado Prop 122 creates a regulated framework (service center rules under development). No other state-level exemptions.
🇲🇽 Mexico
Unscheduled / Grey5-MeO-DMT not specifically scheduled in Mexican law. Bufo ceremonies operate openly in Tulum and Playa del Carmen in retreat settings. No specific legal prohibition on possession.
🇯🇲 Jamaica
UnscheduledLike psilocybin, 5-MeO-DMT is not specifically scheduled. Some retreat centers offer it alongside psilocybin. Legal access for visitors.
🇳🇱 Netherlands
Controlled5-MeO-DMT is a controlled substance under List I of the Dutch Opium Act. Unlike psilocybin truffles, no legal 5-MeO-DMT access pathway exists.
🇨🇴 Colorado, USA
Prop 122 FrameworkThe only US jurisdiction with a regulatory framework for 5-MeO-DMT. DORA is developing service center rules. Personal possession (limited amounts) decriminalized.
🇨🇦 Canada
Schedule III5-MeO-DMT is Schedule III under Canada's CDSA. Health Canada has authorized clinical research. Personal possession remains illegal.
🇧🇷 Brazil
ComplexBrazil's religious exemptions (for ayahuasca) may extend to plant-based 5-MeO-DMT preparations in some contexts. Synthetic status unclear.
🇵🇹 Portugal
Decrim for Personal UsePortugal decriminalized personal possession of all drugs in 2001. 5-MeO-DMT in personal amounts would not result in criminal charges — but no therapeutic access pathway.
Active Research Programs (June 2026)
| Institution | Study | Status | Notes |
|---|---|---|---|
| Johns Hopkins | Synthetic 5-MeO-DMT for MDD (Phase 2) | Active / Expanding | Lead: Alan Davis, PhD. Building on 2023 pilot. Recruiting for expanded cohort. |
| UC San Diego | 5-MeO-DMT for existential distress + TRD | Recruiting | Focus on terminal illness anxiety and treatment-resistant depression. |
| Beckley Foundation (UK) | 5-MeO-DMT neuroimaging study | Active | fMRI during 5-MeO-DMT sessions — mapping neural correlates of ego dissolution. |
| MAPS Canada | 5-MeO-DMT for PTSD | Early Phase | Parallel track to MDMA PTSD program. Very early stage. |
| Various — Mexico | Observational studies at retreat centers | Ongoing | Several Mexican centers collaborating with US researchers on outcome tracking. |
Oracle Predictions: 5-MeO-DMT Regulatory Trajectory
14%
FDA approval for 5-MeO-DMT for depression or existential distress by 2030
41%
FDA grants Breakthrough Therapy Designation to a 5-MeO-DMT program by 2028
67%
Colorado Prop 122 service centers begin offering 5-MeO-DMT sessions by 2027
52%
Phase 3 randomized trial of synthetic 5-MeO-DMT launches by 2028
29%
Two or more additional US states add 5-MeO-DMT to natural medicine frameworks by 2029
78%
Synthetic 5-MeO-DMT definitively supersedes toad-sourced material in all clinical and licensed settings by 2027
Agent Perspectives
FDA Regulatory Reviewer
"5-MeO-DMT presents an interesting regulatory picture. The evidence base is much smaller than psilocybin — we're talking Phase 2 pilot data. But the scalability argument is real: a 30-minute session versus an 8-hour session changes the pharmacoeconomics of therapy delivery entirely. If the Phase 2 signal holds in a properly powered Phase 3, the FDA would be looking at a potentially more accessible treatment model. Breakthrough Therapy Designation is possible if the Phase 3 design is solid. We'd need to see robust safety data — particularly cardiac — before NDA consideration."
Neuropharmacologist
"The 5-HT1A agonism distinguishes 5-MeO-DMT from psilocybin mechanistically. 5-HT1A activation is anxiolytic and associated with neurogenesis — it's actually the mechanism of buspirone and partially of SSRIs at the autoreceptor level. Combining intense 5-HT2A-mediated neuroplasticity with 5-HT1A anxiolysis may explain why the ego dissolution is generally reported as peaceful rather than terrifying, even though it's more complete than psilocybin. That's a meaningful pharmacological distinction with therapeutic implications."
MAPS Researcher
"The scalability case for 5-MeO-DMT is compelling but I want to push back on a common misunderstanding: a 30-minute drug experience doesn't mean 30 minutes of clinical time. You still need preparation sessions, medical screening, a trained facilitator present during the session, and integration support afterward. The session duration is shorter, but the total care time is maybe 30% less than psilocybin — not 90% less. The idea that 5-MeO-DMT will make psychedelic therapy as scalable as prescribing an antidepressant is premature."
Investigative Journalist
"The toad venom issue is genuinely underreported. The Sonoran Desert toad is experiencing real population pressure from demand for ceremonial use. Multiple documented deaths and cardiac events have occurred in uncontrolled bufo ceremonies — including some retreat settings with no medical staff present. The conservation community and the public health community have largely separate conversations about this, but they converge on the same conclusion: synthetic 5-MeO-DMT is the responsible path forward. The 'natural' toad venom framing in some retreat marketing is a conservation problem as well as a safety one."
Safety: What You Need to Know Before Accessing 5-MeO-DMT
| Risk Category | Toad Venom | Synthetic 5-MeO-DMT |
|---|---|---|
| Cardiac risk | HIGH — bufadienolides can cause arrhythmias | LOW — serotonergic only; standard cardiac screening applies |
| MAOI interaction | LETHAL — never combine | LETHAL — never combine |
| Dosing accuracy | Variable (depends on individual toad) | Precise (pharmaceutical grade) |
| Psychological intensity | Very high — complete ego dissolution common | Very high — complete ego dissolution common |
| Nausea / vomiting | Common (bufotenin contribution) | Less common |
| Conservation impact | Significant | None |
Absolute contraindications: MAO inhibitors (including Syrian rue/harmalas), personal or family history of psychosis or schizophrenia, active cardiac conditions (particularly with toad venom), pregnancy, lithium. Anyone with a history of cardiac arrhythmia should undergo careful evaluation before any 5-MeO-DMT exposure.
Frequently Asked Questions
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a psychedelic tryptamine found naturally in Sonoran Desert toad venom, several plants, and synthesized in labs. Unlike N,N-DMT (the compound in ayahuasca's visionary component), 5-MeO-DMT is primarily a 5-HT1A agonist — producing a dramatically different experience: complete ego dissolution and oceanic boundlessness rather than complex visual hallucinations. The experience lasts 15-30 minutes (vs. 4-6 hours for psilocybin). By most measures of mystical experience intensity, it produces effects comparable or superior to high-dose psilocybin in a fraction of the time.
5-MeO-DMT is Schedule I under US federal law. Synthetic 5-MeO-DMT is definitively Schedule I. Bufo toad venom possession would also constitute Schedule I possession. The one significant exception: Colorado's Prop 122 (2022) includes 5-MeO-DMT in its regulated natural medicine framework — service center rules are under development. Personal possession of small amounts is decriminalized in Colorado. In Mexico, 5-MeO-DMT is unscheduled and Bufo ceremonies operate openly in retreat settings.
Two key Hopkins studies. First, a 2019 survey (n=362 naturalistic users) found 80% reported improvements in depression, 79% in anxiety, and 68% rated it among the most meaningful experiences of their lives. Second, a 2023 Phase 2 pilot (n=10) of synthetic 5-MeO-DMT for MDD found significant depression reduction (MADRS) at 1-week and 1-month follow-ups — 60% response rate, 40% remission, comparable to psilocybin outcomes in a 30-minute session. These are encouraging early findings requiring larger randomized trials.
Bufo toad venom contains 5-MeO-DMT plus bufotenin plus bufadienolides (cardiotoxic steroids that can cause cardiac arrhythmias). Synthetic 5-MeO-DMT is chemically pure, precisely dosable, free of cardiotoxic compounds, and causes no harm to the endangered Sonoran Desert toad. All clinical trials use synthetic material. From every relevant perspective — safety, precision, conservation — synthetic 5-MeO-DMT is strongly preferred over toad venom.
Legal access in 2026: Mexico (unscheduled; Bufo ceremonies widely available in Tulum/Playa del Carmen in retreat settings), Jamaica (unscheduled), Colorado (Prop 122 framework being implemented), and US clinical trials at Johns Hopkins and UCSD. For anyone with a clinical condition, clinical trials are the safest and most evidence-based option. Mexico retreat access carries more variable safety standards — verify any provider's medical supervision protocols and avoid settings where 5-MeO-DMT follows ayahuasca (MAOI interaction risk).
Key risks: (1) Psychological intensity — complete ego dissolution can be severely distressing without preparation and support. (2) Bufo venom cardiac risk from bufadienolides — absent in synthetic 5-MeO-DMT. (3) Drug interactions: NEVER combine with MAO inhibitors (Syrian rue, harmalas, pharmaceutical MAOIs) — this can be lethal via serotonin syndrome. (4) Seizure risk at high doses. (5) Hypertensive episodes. Contraindications: history of psychosis/schizophrenia, cardiac conditions, MAOI use, lithium, pregnancy. This compound requires more careful screening than psilocybin.
Related Research
🔮 OOTWOracle tracks 5-MeO-DMT regulatory developments daily
8 AI agents monitor FDA actions, clinical trial registrations, state legislation, and research publications — providing confidence-scored predictions on the regulatory trajectory of every major psychedelic compound.
View Today's Oracle Report →